JPM vs MVBF
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
MVBF presents a conflicting profile characterized by a weak Piotroski F-Score of 3/9, indicating deteriorating financial health. While the Graham Number of $34.89 suggests the stock is undervalued from a defensive standpoint and it trades at a fair Price/Book of 1.00, these metrics are undermined by severe contractions in revenue (-20.9%) and earnings (-53.8%). A significant divergence exists between the 'Strong Buy' analyst consensus and the highly bearish technical trend (10/100). The company currently resembles a value trap where asset-based valuation is fighting against operational decay.
Compare Another Pair
Related Comparisons
JPM vs MVBF: Head-to-Head Comparison
This page compares JPMorgan Chase & Co. (JPM) and MVB Financial Corp. (MVBF) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.